Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Actelion
While there are no FDA approved therapies for the treatment of IPF, there are therapies that have been shown to be effective in ameliorating the effects of pulmonary hypertension in patients with PAH (pulmonary arterial hypertension), including inhaled iloprost. However, these therapies have not been used extensively in patients with IPF who have pulmonary hypertension as a complication. The potential benefits of treatment of pulmonary hypertension complicating IPF include: improvement in pulmonary hemodynamics, with reduction in pulmonary artery pressure and pulmonary vascular resistance, and increase in cardiac output.
Age
40–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of idiopathic pulmonary fibrosis according to American Thoracic Society criteria
Diagnosis of elevated pulmonary pressures
Six minute walk distance between 50-380
NYHA functional class II - IV
You may not be if
Pulmonary fibrosis related to a systemic disorder
Significant chronic obstructive pulmonary disease
History of thromboembolic disease within the previous year
Awaiting lung transplantation within next 36 weeks
Active lung infection
Survival prognosis of less than 1 year
Significant left-sided heart failure, active coronary artery disease